We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
First therapy targeting Parkinson's proteins enters clinical trials.
- Authors
Dolgin, Elie
- Abstract
The article discusses the clinical trial of a therapy targeting alpha-synuclein which is a Parkinson's protein. Parkinson's vaccine from Vienna, Austria-based AFFiRiS AG is a short peptide that initiates the antibody to attack and clear the alpha-synuclein protein in cell membrane. It states that brain inflammation is the risk of immunization against a neurotoxic protein alpha-synuclein. It mentions that the Elan Corp. is developing antibody therapy and drugs for the Parkinson's disease.
- Subjects
PARKINSON'S disease treatment; CLINICAL trials; ALPHA-synuclein; AFFIRIS AG; ENCEPHALITIS; ELAN Corp. PLC
- Publication
Nature Medicine, 2012, Vol 18, Issue 7, p992
- ISSN
1078-8956
- Publication type
Article
- DOI
10.1038/nm0712-992b